Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

L-Serine and Reduced Deoxysphinganine Level

Doses used in studies

mg/kg/day: 400 (median 400, IQR 400–400) — 1 study

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
There were no serious adverse effects related to l-serine.
from: Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy

1 of 1 paper

Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1.
- 2019-01-22
- RCT · n = 18
- Neurology 92(4)
- - Vera Fridman
  - Saranya Suriyanarayanan
  - Peter Novak
  - William David
  - Eric A Macklin
  - Diane McKenna-Yasek
  - Kailey Walsh
  - Razina Aziz-Bose
  - Anne Louise Oaklander
  - Robert Brown
  - Thorsten Hornemann
  - Florian Eichler
- PubMed: 30626650
- DOI: 10.1212/wnl.0000000000006811
2 Insights on
- Reduced Deoxysphinganine Level
- High evidence
- Clinical
Concomitantly, deoxysphinganine levels dropped in l-serine-treated but not placebo-treated participants (59% decrease vs 11% increase; p < 0.001)
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
400 mg/kg/day